Information
News
Clinical Study “Relaxin for Heart Failure with preserved Ejection Fraction (HFpEF)”
Relaxera is designing a clinical phase II study demonstrating the beneficial and pleiotropic effects of relaxin in heart failure with preserved ejection fraction (HFpEF). Relaxera plan to commence this study within the next 3 years. The selection of patients for this upcoming study is the responsibility of the Prinicipal Investigators (the physicians in charge of conducting the study). Only these doctors - see list of Principal Investigators* - decide on patient enrolment. If you are interested [...]
Relaxera and University of Pittsburgh announce research cooperation
As of December 2017, Relaxera and the group of Prof. Guy Salama (Heart and Vascular Institute of The University of Pittsburgh) entered into a research cooperation regarding the effects of relaxin in an animal model of HFpEF (“aged rat”). The focus of this research will, among others, be on relaxin’s effects towards isoform expression and phosphorylation of titin. Titin is a giant protein acting like a spring to determine compliance in relaxed heart and skeletal muscle; [...]
Events
D-A-C-H-Region Congress “Heart Failure”
The Heart Failure Congress takes place September 28 – 30, 2023, in Göttingen, Germany. The lectures focus on heart failure treatment options, HFpEF, on electrophysiology, diagnostics, operative and intervention heart failure treatment and additional with a view on several comorbidities. Find here the complete program for three days. On September 28, the session “Pipeline for the therapy of heart failure” (at 1 pm) includes a presentation by Thomas Dschietzig about relaxin-2 as treatment option.
9th International Conference on Relaxin and Related Peptides
Relaxera is supporting and attending the 9th International Conference on Relaxin and Related Peptides. Featured presenters cover all aspects of basic biology and physiology, plus potential clinical applications of relaxin and related peptides. One of our contributions will be the chairing of the session “Circulatory and Vasculatory Actions". As well we present new research results for cardioprotective effects of relaxin-2. Join us to discuss with leading scientists from around the world, learn latest news from the [...]
Interview Digital Health TV 2022
Two interviews with the Bavarian Health Management GmbH in Germany about "Relaxin and Heart Failure" and "Relaxin and Transplantation Medicine". Prof. Andreas Grün is interviewing Prof. Dr. Thomas B. Dschietzig, CEO Relaxera. (in German language) interview 1 - Relaxin and heart failure; get the summary here. interview 2 - Relaxin and transplantation medicine; get the summary here.
Presentation at European Society of Cardiology (ESC) Congress 2022 in Barcelona
First results of our cooperation with University of Pittsburgh Medical Center, UPMC, were presented during the ESC congress 2022 in Barcelona by Prof. Dr. Guy Salama in the session "HFpEF and HFmrEF: what’s new in treatment" - “The therapeutic potential of relaxin for heart failure with preserved ejection fraction” You will learn about relaxin-2-[...]